The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

The information provided here does not include promotional content or endorsements of the therapy's effectiveness, as its success will depend on the outcomes of the ongoing trial. Merck and Moderna ...

Some are leveraging Merck's partnership with Daiichi Sankyo to develop antibody drug conjugates ("ADCs"), a pioneering new type of dual action therapy (two candidates to date - ifinatamab ...

TROY, Mich., Oct. 25, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Merck & Co. (NYSE: MRK) as its "Stock to Study" and ...

“DNA repair defects are a frequent hallmark of tumor cells and a major cause of resistance to cancer therapy,” said Dr. David Weinstock, vice president, discovery oncology, Merck Research Laboratories ...